Issue 123 • October 2022

Nanorobots: small solutions to big delivery problems 

Brazil: an untapped market for big pharma manufacturing

Foreign investments amplify the nucleic acid therapeutics field

In association with

Exploring the promise of billion-dollar KRAS drugs

KRAS mutations are one of the most prevalent drivers of cancer, yet they were long considered ‘undruggable’; a new wave of drugs is changing that

In association with

Issue 122

Brought to you by

02/24/2024 01:17:30
  • Home | The promise of billion-dollar KRAS drugs
  • In this issue
  • Contents
  • Wek-tec Company Insight
  • CSafe Global
  • Briefing
  • Industry news
  • The pharma industry briefing
  • SHL Medical Company Insight
  • SHL Medical
  • Agilent
  • Comment
  • The potential of virtual reality-based therapy for serious mental disorders
  • Brazil: an untapped market for big pharma manufacturing
  • More big wins for the AstraZeneca-Daiichi Sankyo collaboration
  • Dry powder inhalers carry potential to decrease greenhouse emissions
  • Black participants severely underrepresented in global oncology studies
  • Polio outbreak in New York state due to low vaccination coverage
  • Mimotopes Company Insight
  • Mimotopes
  • Skyepharma
  • In Depth
  • Exploring the promise of billion-dollar KRAS drugs
  • Nanorobots: small solutions to big delivery problems
  • Foreign investments amplify the nucleic acid therapeutics field
  • Going beyond the mirage of complete skin clearance in psoriasis
  • As Russia’s clinical trials sector falls, Ukraine rebuilds
  • CMO Moves: Regulatory catalysts for drug manufacturing—September
  • Dr. Paul Lohmann
  • Baxter
  • In Data
  • Top pharma companies best positioned to weather industry disruption
  • Which pharma companies lead the way in artificial intelligence?
  • North America sees a hiring jump in big data roles in pharma
  • Cloud computing mentions decrease in pharma filings
  • Events
  • Next issue
09/21/2022 00:00:00